Sabby Management’s Biocept, Inc. BIOC Stock Holding History

Sabby Management’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-987	Closed	-$10.1K	–	114
2023 Q1	$10.1K	Sell	987 -30	-3%	-$434	0.01%	87
2022 Q4	$16.2K	Hold	1,017	–	–	0.01%	97
2022 Q3	$28K	Hold	1,017	–	–	0.04%	99
2022 Q2	$29K	Hold	1,017	–	–	0.02%	114
2022 Q1	$71K	Buy	1,017 +395	+64%	+$31K	0.01%	126
2021 Q4	$68K	Buy	+622	New	+$71.6K	0.01%	164
2021 Q3	–	Sell	-2,563	Closed	-$322K	–	212
2021 Q2	$322K	Buy	2,563 +514	+25%	+$69.6K	0.05%	120
2021 Q1	$313K	Buy	2,049 +996	+95%	+$181K	0.06%	122
2020 Q4	$140K	Buy	+1,053	New	+$150K	0.03%	92
2019 Q1	–	Sell	-192	Closed	-$49K	–	141
2018 Q4	$49K	Sell	192 -283	-60%	-$142K	0.01%	95
2018 Q3	$392K	Buy	475 +455	+2,275%	+$580K	0.05%	81
2018 Q2	$36K	Buy	20 +10	+100%	+$20.2K	0.01%	124
2018 Q1	$27K	Sell	10 -97	-91%	-$364K	﹤0.01%	147
2017 Q4	$668K	Buy	+107	New	+$846K	0.06%	96
2017 Q1	–	Sell	-46	Closed	-$319K	–	335
2016 Q4	$319K	Buy	+46	New	+$385K	0.02%	225

Other funds holding BIOC

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sabby Management's BIOC Position: Q2 2023 in Review

Sabby Management sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 987 shares — an estimated $10.1K sold.

Sabby Management first reported a position in BIOC in Q4 2016 and held it in 15 quarters. The position peaked at $668K in Q4 2017. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

Sabby Management reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
Sabby Management sold 987 Biocept, Inc. shares in Q2 2023, an estimated $10.1K.
Sabby Management first reported a position in Biocept, Inc. in Q4 2016 and held it in 15 quarters.
Sabby Management's Biocept, Inc. position peaked at $668K in Q4 2017.
11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Sabby Management's 13F filing for Q2 2023, filed 14 Aug 2023.